Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,002,272
  • Shares Outstanding, K 184,447
  • Annual Sales, $ 13,453 M
  • Annual Income, $ 4,431 M
  • 60-Month Beta 1.02
  • Price/Sales 3.10
  • Price/Cash Flow 7.12
  • Price/Book 3.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 8.27
  • Number of Estimates 24
  • High Estimate 9.15
  • Low Estimate 7.80
  • Prior Year 7.40
  • Growth Rate Est. (year over year) +11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
219.70 +2.69%
on 10/03/19
242.71 -7.05%
on 09/23/19
-13.10 (-5.49%)
since 09/17/19
3-Month
215.77 +4.55%
on 09/04/19
246.99 -8.66%
on 07/23/19
-3.84 (-1.67%)
since 07/17/19
52-Week
215.77 +4.55%
on 09/04/19
344.00 -34.42%
on 01/23/19
-112.63 (-33.30%)
since 10/17/18

Most Recent Stories

More News
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth

RHHBY : 36.5600 (+2.29%)
GILD : 65.23 (-0.18%)
AMGN : 203.56 (+0.17%)
BIIB : 225.60 (-0.93%)
Biogen Strengthens MS & SMA Portfolio as Competition Lurks

Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon...

RHHBY : 36.5600 (+2.29%)
NVS : 87.23 (+0.26%)
ALKS : 17.73 (-2.72%)
BIIB : 225.60 (-0.93%)
The Zacks Analyst Blog Highlights: Verizon Communications, PepsiCo, Biogen, Bank of New York ??? Mellon and Cerner

The Zacks Analyst Blog Highlights: Verizon Communications, PepsiCo, Biogen, Bank of New York ??? Mellon and Cerner

BK : 44.38 (-0.14%)
CERN : 68.11 (-0.07%)
VZ : 60.41 (+0.20%)
PEP : 136.96 (+0.40%)
BIIB : 225.60 (-0.93%)
Top Stock Reports for Verizon, PepsiCo & Biogen

Top Stock Reports for Verizon, PepsiCo & Biogen

VZ : 60.41 (+0.20%)
SYK : 215.56 (-0.09%)
PEP : 136.96 (+0.40%)
CERN : 68.11 (-0.07%)
BK : 44.38 (-0.14%)
BIIB : 225.60 (-0.93%)
29.3% Return Seen to Date on SmarTrend Biogen Inc Call (BIIB)

SmarTrend identified a Downtrend for Biogen Inc (NASDAQ:BIIB) on February 7th, 2019 at $316.11. In approximately 8 months, Biogen Inc has returned 29.33% as of today's recent price of $223.40.

BIIB : 225.60 (-0.93%)
NURTURE study shows pre-symptomatic Spinal Muscular Atrophy (SMA) infants treated with SPINRAZA(TM) (nusinersen injection) attained positive results

Biogen Canada is pleased to announce results from the NURTURE study, which demonstrated that infants who initiated treatment with SPINRAZATM (nusinersen injection) prior to the onset of clinical symptoms...

BIIB : 225.60 (-0.93%)
Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA(R) (nusinersen) Published in Neuromuscular Disorders

-- Motor milestones achieved included 100 percent of participants sitting without support and 88 percent walking independently; unprecedented outcomes in comparison to the natural history of the disease...

BIIB : 225.60 (-0.93%)
IONS : 56.54 (-1.87%)
Look for Shares of Biogen Inc to Potentially Rebound after Yesterday's 1.83% Sell Off

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $228.19 to a high of $234.04. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $228.36...

BIIB : 225.60 (-0.93%)
SmarTrend Watching for Potential Rebound in Shares of Biogen Inc After 1.83% Loss

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $228.19 to a high of $234.04. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $228.36...

BIIB : 225.60 (-0.93%)
Biogen Announces Leadership Update

Dr. Alfred Sandrock is named Executive Vice President, Research and Development and continues as Chief Medical Officer

BIIB : 225.60 (-0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 231.51
1st Resistance Point 228.55
Last Price 225.60
1st Support Level 223.06
2nd Support Level 220.53

See More

52-Week High 344.00
Fibonacci 61.8% 295.02
Fibonacci 50% 279.89
Fibonacci 38.2% 264.76
Last Price 225.60
52-Week Low 215.77

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar